A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

• Status: Completed
• Trial end date: 2011-11-01

Summary

The purpose of this study is to evaluate the safety and dose regimen of CNTO 888 when administered to patients with solid tumors in combination with 4 standard of care chemotherapy regimens.

• Phase: Phase 1

Details

• Lead Sponsor: Centocor, Inc.
• Treatments: Albumin-Bound Paclitaxel; Antibodies, Monoclonal; Carboplatin; Docetaxel; Doxorubicin; Gemcitabine; Liposomal doxorubicin; Paclitaxel